Suchergebnisse - (Person:"Barreiro, Pablo")

PubPharm (9)

1

Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C

enthalten in: Antiviral therapy | 2015

von Labarga, P. | Fernández-Montero, J. | de Mendoza, C. | +2

2

Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy

enthalten in: Antiviral therapy | 2014

von Fernández-Montero, J. | Barreiro, P. | Vispo, E. | +5

3

Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C

enthalten in: Antiviral therapy | 2013

von Soriano, V. | Vispo, E. | de Mendoza, C. | +6

4

Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir

enthalten in: Antiviral therapy | 2008

von Vispo, E. | Barreiro, P. | Pineda, J. | +9

5

Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b

enthalten in: Antiviral therapy | 2008

von Vispo, E. | Barreiro, P. | Rodriguez-Nóvoa, S. | +6

6

Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin

enthalten in: Antiviral therapy | 2007

von Soriano, V. | Miralles, C. | Berdún, M. | +19

7

Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4

enthalten in: Antiviral therapy | 2005

von Soriano, V. | Núñez, M. | Sánchez-Conde, M. | +5

8

Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C

enthalten in: Antiviral therapy | 2005

von Núnez, M. | Camino, N. | Ramos, B. | +12

9

Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies

enthalten in: Antiviral therapy | 2004

von Soriano, V. | Maida, I. | Núñez, M. | +4

1
[1]